Preoperative total cholesterol and axillary lymph node burden in breast cancer: an exploratory analysis with a preliminary nomogram - Scorecard - MDSpire

Preoperative total cholesterol and axillary lymph node burden in breast cancer: an exploratory analysis with a preliminary nomogram

  • By

  • Xingxing Ouyang

  • Lisha Wu

  • Yanhua Zhou

  • July 1, 2026

  • 0 min

Share

Clinical Scorecard: Association of Preoperative Serum Total Cholesterol Levels with Axillary Lymph Node Involvement in Breast Cancer: An Exploratory Study and Initial Nomogram Development

At a Glance

CategoryDetail
ConditionBreast Cancer
Key MechanismsAssociation between preoperative serum total cholesterol levels and axillary lymph node burden.
Target PopulationFemale patients with primary operable breast cancer undergoing modified radical mastectomy.
Care SettingTertiary cancer center

Key Highlights

  • High axillary lymph node burden defined as more than four metastatic lymph nodes.
  • 25% of patients exhibited high axillary lymph node burden.
  • Higher total cholesterol levels associated with increased odds of high nodal burden (OR = 1.56 per 1 mmol/L increase).
  • Model performance showed limited discriminative ability (C-index = 0.61).
  • Further validation in larger studies is required.

Guideline-Based Recommendations

Diagnosis

  • Assess preoperative serum total cholesterol levels in patients with breast cancer.

Management

  • Consider axillary lymph node burden in treatment planning for breast cancer.

Monitoring & Follow-up

  • Monitor total cholesterol levels as part of preoperative assessment.

Risks

  • High axillary lymph node burden may necessitate post-mastectomy radiotherapy and intensified systemic treatment.

Patient & Prescribing Data

Female patients with histologically confirmed invasive breast carcinoma.

Preoperative total cholesterol levels may provide insights into nodal involvement.

Clinical Best Practices

  • Utilize logistic regression analysis for assessing associations in clinical studies.
  • Incorporate tumor size in risk estimation models for axillary lymph node burden.

Related Resources & Content

Original Source(s)

Related Content